Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Abstract

The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.

• Authors: Joshua D Hartzell, Robert Neff, Julie Ake, Robin Howard, Stephen Olson, Kristopher Paolino, Mark Vishnepolsky, Amy Weintrob, Glenn Wortmann
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 48 Issue 12 Pg. 1724-8 (Jun 15 2009) ISSN: 1537-6591 [Electronic] United States
• PMID: 19438394 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• colistinmethanesulfonic acid
• Colistin

Topics

• Adult
• Anti-Bacterial Agents (administration & dosage, adverse effects, therapeutic use)
• Bacterial Infections (drug therapy)
• Colistin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Female
• Humans
• Incidence
• Injections, Intravenous
• Male
• Renal Insufficiency (chemically induced)
• United States
• Withholding Treatment
• Young Adult